Financial Data and Key Metrics Changes - Fourth quarter net sales reached $215.7 million, reflecting an 8% year-over-year growth on a constant currency basis, with record performance across all major product lines [18][50] - Positive free cash flow of $15.2 million in Q4 and $21 million in the second half of 2024, a significant improvement from negative $30 million in the first half of 2024 [15][44] - Non-GAAP adjusted EBITDA of $23.9 million in Q4, representing growth at nearly 3x revenue with 130 basis points of margin expansion [43] Business Line Data and Key Metrics Changes - U.S. spine fixation revenue grew 12%, driven by strong demand for recently launched products and a 30% increase in global 7D FLASH Navigation System placements [19][21] - Bone Growth Therapies (BGT) revenue grew 9% to $63.9 million in Q4, with 10% growth in the BGT fracture channel [25][41] - Global orthopedics business delivered record net sales in Q4, with 18% growth compared to the prior year, led by a 21% increase in U.S. sales [28][42] Market Data and Key Metrics Changes - The international business grew 17% year-over-year, with variability expected due to the nature of stocking distributor and tender orders [42] - The U.S. spinal fixation market saw Orthofix outperforming the market growth rate significantly, particularly in the lateral portfolio which grew 33% [19][20] Company Strategy and Development Direction - The company is focused on long-term profitable growth, emphasizing innovation and enhancing market penetration through a comprehensive portfolio [16][17] - A new leadership team has been established to align the organization with a cohesive growth strategy [10] - The company plans to discontinue non-core products, including the M6 artificial discs, to focus resources on more profitable growth opportunities [46][47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustainable growth trends and the strength of the differentiated and expanding portfolio [37] - The company anticipates continued above-market growth across all business lines, driven by a robust innovation pipeline and strategic focus on enabling technologies [35][61] - Management highlighted the importance of disciplined capital deployment and the potential for M&A opportunities in the future [70][71] Other Important Information - The company received FDA clearance for the FLASH EVD cranial navigation product, expanding its footprint in the hospital market [22] - The anticipated launch of several new products in 2025, including the Reef L Lateral Lumbar Interbody, is expected to enhance market share [24][32] Q&A Session Summary Question: Can you provide more color on the discontinuation of M6? - Management indicated that the decrease in demand for M6 did not justify further investment, aiming for a cleaner slate in 2025 to enhance growth potential [66][68] Question: What are your current thoughts on M&A? - Management is focused on executing current strategies but is open to M&A opportunities that fit the portfolio, supported by a strengthened balance sheet [70][71] Question: Any updates on the 7D system adoption? - Management reported a record year for 7D, with a 150% year-over-year increase in earn-out agreements, indicating strong demand and performance [72][75] Question: Is there any margin impact from exiting the M6 product line? - Management will provide more details on the historical financial impact in the next earnings call but has accounted for it in the current guidance [78][79] Question: Will there be any gaps in the U.S. spine portfolio due to product phase-out? - Management believes there will not be significant gaps as the M6 product will be phased out gradually, allowing for resource reallocation to more strategic areas [80][82] Question: Which upcoming product launch are you most excited about? - Management highlighted the full commercial launch of the new interbody product in spine and the Elevate system in orthopedics as key growth drivers [84][86]

Clear Course for Profitable Growth 4Q and Full-Year 2024 Earnings Call February 25, 2025 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, intentions, plans, expectations, estimates, forecasts and projections. In some cases, you can id ...

Orthofix (OFIX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -66.67%. A quarter ago, it was expected that this medical device maker would post a loss of $0.14 per share when it actually produced earnings of $0.07, delivering a surprise of 150%.Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 3451 Plano Parkway, Lewisville, Texas 75056 (Address of principal executive offices) (Zip Code) (214) 937-2000 (Registrant's telephone number, including area code) For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commiss ...

Exhibit 99.1 News Release Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies LEWISVILLE, Texas — February 25, 2025 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year ...

Orthofix Medical Inc. (NASDAQ:OFIX) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Julie Dewey - Chief IR and Communications Officer Massimo Calafiore - President and CEO Julie Andrews - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Iseult McMahon - BTIG Jason Wittes - ROTH MKM Operator Good morning, and welcome to the Orthofix Third Quarter 2024 Earnings Call. I am Fran, and I'll be the operator assisting you today. [Operator Instructions]. ...

SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of former SeaSpine Holdings Corporation shareholders that purchased or otherwise acquired newly issued Orthofix Medical Inc. (NASDAQ: OFIX) stock in exchange for SeaSpine shares pursuant to the January 5, 2023 stock-for-stock transaction by which Orthofix merged with and acquires SeaSpine. Orthofix is a global spine and orthopedics company that offers biologics, spinal hardware, bone growt ...

Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.14 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 150%. A quarter ago, it was expected that this medical device maker would post a loss of $0.13 per share when it actually produced earnings of $0.05, delivering a surprise of 138.46%. Over the last four quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 98-1340767 (State or other jurisd ...

Exhibit 99.1 News Release Orthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and Introduces New Three-Year Financial Targets Building on Positive Momentum from Compelling Combination of Profitable, Above-Market Growth with a Stronger Financial Profile LEWISVILLE, Texas — November 7, 2024 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2024, reiterated its ...